INTRODUCTION
Modulation of co-inhibitory and co-stimulatory immune checkpoint molecules on tumor-reactive lymphocytes has emerged as a promising therapeutic strategy for a variety of cancers (Hodi et al., 2010; Larkin et al., 2015; Ribas et al., 2015; Robert et al., 2011 Robert et al., , 2014 Robert et al., , 2015 Weber et al., 2015; Wolchok et al., 2013) . Monoclonal antibodies (mAbs) targeting immune checkpoint molecules were initially thought to act solely via regulation of effector T (Teff) cell responses, but recent pre-clinical data in mouse models demonstrates that the activity of certain immune modulatory mAbs (such as anti-CTLA-4, -GITR, and -OX40) may extend beyond simple receptor stimulation or blockade, relying upon an additional capacity to deplete regulatory T (Treg) cells by antibody-dependent cell-mediated cytotoxicity (ADCC) (Bulliard et al., 2013 (Bulliard et al., , 2014 Selby et al., 2013; Simpson et al., 2013) .
Significance
Understanding the mechanisms underlying the activity of antibodies that modulate immune checkpoints is fundamental. This study demonstrates that the activity of anti-CTLA-4 antibodies depends, at least in part, on the depletion of tumor-infiltrating regulatory T (Treg) cells in the context of human FcgRs and human IgGs. Enhanced antibody-dependent cell-mediated cytotoxicity, either by Fc optimization, or the presence of FcgR variants with high binding affinity, improves therapeutic outcomes, but only in highly immunogenic tumors. The combination of mutational burden and FcgR polymorphism status should be considered in the selection of patients likely to respond to anti-CTLA-4. The same rules may apply to the design of immune modulatory antibodies directed against additional targets with high relative expression on Treg cells. (Peggs et al., 2009) . Whilst binding of anti-CTLA-4 to Teff and Treg cells serves to promote expansion of both compartments via its immune modulatory activity, high levels of surface CTLA-4 on tumor-infiltrating Treg cells relative to Teff cells promotes preferential depletion of Treg cells at the tumor site, resulting in an increase in the intra-tumoral Teff/Treg cell ratio and tumor rejection (Bulliard et al., 2013; Selby et al., 2013; Simpson et al., 2013) . The observed dual activity of anti-CTLA-4 mAbs relies not only upon higher expression of the target molecule on Treg relative to Teff cells at the tumor site but also upon antibody isotype and enrichment of Fc-gamma receptor (FcgR)-expressing innate effector cell subsets with capacity for ADCC within the tumor microenvironment (Simpson et al., 2013) .
Ipilimumab, a human IgG1 mAb directed against CTLA-4, mediates durable remissions in patients with advanced melanoma, although such responses are limited to a small subset (Hodi et al., 2010; Robert et al., 2011; Schadendorf et al., 2015) . Despite its potentially depleting isotype, the contribution of ADCC and role of FcgRs in the activity of ipilimumab in vivo remains unclear. Two recent clinical studies have identified a reduction in tumor-infiltrating Treg cells after ipilimumab therapy (Romano et al., 2015; Tarhini et al., 2014) . Moreover, in vitro studies demonstrate that ipilimumab depletes CTLA-4-expressing Treg cells in the presence of FcgR-expressing monocytes and natural killer (NK) cells, consistent with predicted binding affinity for activatory FcgRs (Jie et al., 2015; Romano et al., 2015) . A second anti-CTLA-4 mAb, tremelimumab, has also displayed activity in early phase studies (Comin-Anduix et al., 2016) . In contrast to ipilimumab, a human IgG2 isotype was selected during the pre-clinical design of tremelimumab to minimize potential ADCC activity (Hanson et al., 2004) , thus arguing against a role for Treg cell depletion in the activity of anti-CTLA-4 mAbs in humans.
Perhaps the strongest evidence for a role of FcgR-mediated effector function in antibody-based cancer therapies derives from clinical studies demonstrating an association between clinical responses and specific alloforms of activating hFcgRs. Single-nucleotide polymorphisms (SNPs) in FCGR2A (H131R) and FCGR3A (V158F) have been associated with improved outcomes owing to a higher binding affinity to IgG1 and IgG2, which increases ADCC (Cartron et al., 2002; Musolino et al., 2008; Weng and Levy, 2003; Zhang et al., 2007) . However, there has been no formal assessment of the impact of such polymorphisms on the response to anti-CTLA-4 or other immune modulatory mAbs.
Deciphering the contribution of the antibody fragment crystallizable (Fc)-FcgR interaction to the activity of immune modulatory antibodies has the potential to significantly inform the optimal design of the next generation of therapeutics. Mutagenesis and glycoform engineering of mAbs have been demonstrated to modulate the affinity of Fc-FcgR interaction, with impact upon cytotoxicity in cell-based assays (Duncan et al., 1988; Redpath et al., 1998; Sarmay et al., 1992; Shields et al., 2001 Shields et al., , 2002 . In this context, efficacy studies in mouse models represent an important step in the pre-clinical development of antibody-based therapies. However, reliable translation of such findings across species is often problematic owing to variation in FcgR subtypes, their distribution, and the affinity of individual IgG subclasses in each species. In addition, polymorphisms in human FcgRs may further influence the binding and biological effects of different IgG subtypes (Koene et al., 1997; Warmerdam et al., 1991; Wu et al., 1997) , but their potential contribution to the activity of immune modulatory antibodies has not been explored. Here we sought to determine the contribution of Treg cell depletion to the in vivo anti-tumor activity of anti-CTLA-4 antibodies in the context of human FcgRs and human IgG isotypes.
RESULTS
CTLA-4, GITR, ICOS, and OX40 Are Expressed at Highest Density on Tumor-Infiltrating Treg Cells in Mouse and Human CTLA-4 has been described to be constitutively expressed on Treg cells (Read et al., 2000 (Read et al., , 2006 Wing et al., 2008) and emerging data suggest this may also be relevant to Treg cells infiltrating human tumors (De Simone et al., 2016; Plitas et al., 2016 Figures 1A-1C) , and human solid tumor subtypes including advanced melanoma, early-stage non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) (Figures 1D-1F ). In mice, CTLA-4 expression was evaluated in peripheral blood mononuclear cells (PBMCs), draining lymph Table S1 and Figure S1 . Figure 1F ). CTLA-4 was consistently expressed at low levels on CD8 + T cells within tumors, with a mean MFI lower than that observed among tumor-infiltrating and circulating Treg cells in mouse models and human tumors ( Figures 1C and 1F ). Based on these data, we sought to determine the expression of an extended panel of immune checkpoint molecules of B7 and tumor necrosis factor receptor superfamilies on TIL subsets (Figures 1G and 1H) . Significant heterogeneity in expression profiles was observed between different tumor subtypes, particularly in molecules typically described on Teff cells, including 4-1BB, PD-1, and TIM-3 ( Figure 1G ). The percentage of cells expressing these molecules appeared higher among CD8 + T cells in the more immunogenic MCA205, MC38, and CT26 mouse tumors relative to the poorly immunogenic B16 melanoma and also higher in human melanoma relative to NSCLC and RCC, potentially related to the immunogenic burden of somatic mutations typically associated with these tumor subtypes (Alexandrov et al., 2013) . Despite this, a number of potentially exploitable patterns were observed. Similar to CTLA-4, the co-stimulatory receptors GITR, ICOS, and OX40 were consistently expressed on tumor-infiltrating Treg cells in mouse and human tumors. Although a proportion of CD4 + FoxP3 À and CD8 + T cell subsets also expressed these molecules ( Figure 1G ), the level of expression, based on MFI, was significantly lower than on the Treg cell compartment (Figures 1H and S1A) . This is in contrast to the co-inhibitory molecules PD-1 and TIM-3, which were expressed by all studied T cell subsets but at highest levels among CD8 + T cells in human cancers ( Figure S1B ). Based on the differential expression between Treg and Teff cells, CTLA-4, GITR, and OX40 appear to be potential targets in all three human tumor subtypes for dual activity antibodies with capacity for ADCC of intra-tumoral Treg cells. Such findings are consistent with pre-clinical mouse studies, in which depleting isotypes of anti-GITR and anti-OX40 demonstrated maximal anti-tumor activity in vivo, associated with their ability to enhance effector function with concomitant depletion of tumor-infiltrating Treg cells (Bulliard et al., 2014; Coe et al., 2010) .
Expression Pattern of FcgRs in Human FcgR Mice and Human Tumors
Beyond distribution and density of target molecule expression, the final outcome of antibody-based therapies also depends upon effector function mediated by Fc-FcgR interaction (Furness et al., 2014) . FcgR-dependent mechanisms identified in mouse models are not easily translated to the human setting owing to inter-species variation in FcgR subtypes, expression patterns, and affinity to IgG subclasses. We therefore sought to overcome such challenges with use of a mouse model described to recapitulate human FcgR (hFcgR) structural and functional diversity , comparing FcgR expression profiles with human melanoma in an attempt to validate its translational value. Analysis of cell subsets in draining LNs, spleens, and blood 10 days after subcutaneous inoculation of MCA205, MC38, or B16 tumors in hFcgR mice demonstrated an expression pattern comparable with previous descriptions , with activatory FcgRI (CD64), IIa (CD32a), and IIIa/b (CD16a/b) expressed on monocytic and granulocytic myeloid cells, CD16a additionally detected in a fraction of NK cells, and the inhibitory CD32b present on B cells and myeloid cell subpopulations (Figures 2A and 2B and data not shown) . Although this expression pattern was maintained on tumor-infiltrating leukocytes, the expression levels of all activatory FcgRs appeared higher in the tumor relative to secondary lymphoid organs, particularly on myeloid cells, which were the most abundant leukocyte subpopulation present in murine tumors ( Figure S2A ). This pattern was consistent across all three studied tumor models, although the percentage of expression of CD32a and CD16 appeared lower on innate effector cells in B16 tumors relative to the more immunogenic MC38 and MCA205 models ( Figure S2B ). Of relevance, the absolute number of tumor-infiltrating leukocytes varied between models, with B16 tumors harboring the lowest levels of T cells and innate effector cells relative to MCA205 and MC38 ( Figure S2A ).
Analysis of human melanoma metastases derived from varied anatomical sites, including subcutaneous, LN, and colonic lesions (Table S2) , demonstrated consistent FcgR expression profiles on individual cell subsets, but important differences between tumor and blood ( Figures 2C and 2D (D) Percentage expression of FcgRs in metastatic deposits of human melanoma from (B) (n = 10). Error bars show ±SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S2 and Table S2 . Figure 2D ). Mo/MFs expressed all three activatory FcgRs (CD64, CD32a, and CD16) as well as the inhibitory receptor CD32b. Although FcgR distribution remained similar between circulating and tumor-infiltrating Mo/MFs, all FcgRs, particularly CD32b, were consistently expressed at higher levels on tumor-infiltrating Mo/MFs ( Figure 2D ). In contrast, FcgR expression by circulating and tumor-infiltrating granulocytes appeared similar, with constitutive expression of the activatory receptors CD32a and CD16b ( Figure 2D ). Overall, among all tumor-infiltrating leukocyte subsets, CD32a was the most abundantly expressed FcgR in human tumors and highly expressed in mouse tumors ( Figure S2C ). FcgR expression in hFcgR mice therefore appeared largely comparable with human melanoma, apart from the inhibitory CD32b. As previously described , in the mouse model, CD32b was expressed on circulating B cells and on myeloid cells, whereas, in humans, expression in blood was largely confined to B cells. This could result in a less favorable activatory to inhibitory (A:I) FcgR ratio in secondary lymphoid organs in the mouse model relative to human blood and tumors, thus a lack of ADCC activity in these organ sites might not necessarily be reflective of the periphery in humans. However, given the previously demonstrated requirement for activatory rather than inhibitory FcgRs in the activity of anti-CTLA-4 mAbs (Bulliard et al., 2013; Simpson et al., 2013) and the observation that anti-CTLA-4-mediated Treg cell depletion is confined to the tumor site, this was considered less relevant and the model taken forward for in vivo studies.
Human IgG1 and IgG2 Anti-CTLA-4 Antibodies Induce FcgR-Dependent Cytotoxicity In Vitro Based on the comparable expression profile of CTLA-4 on T lymphocytes and FcgRs on tumor-infiltrating innate effector cell subsets in humans and hFcgR mice, we next evaluated whether anti-CTLA-4 mAbs of a human isotype promoted depletion of intra-tumoral Treg cells in vivo in a similar manner to that mediated by murine FcgRs (Selby et al., 2013; Simpson et al., 2013) .
We therefore constructed chimeric anti-murine CTLA-4 (mCTLA-4) antibodies (based on clone 4F10) with human IgG1, modeling ipilimumab, which has been shown to mediate ADCC in vitro (Romano et al., 2015) . Owing to the abundance of CD32a, the main receptor to which human IgG2 binds, in mouse and human tumors, we also generated a chimeric anti-mCTLA mAb with IgG2, the isotype employed in tremelimumab. These mAbs were compared with mutated IgG1 isotypes with either enhanced binding affinity to activatory CD16a (IgG1 SDALIE ) (Lazar et al., 2006) or no binding to hFcgRs (IgG1 N297A ). Consistent with existing data (Bruhns et al., 2009) , surface plasmon resonance (SPR) analysis of generated antibodies demonstrated binding of IgG1 and IgG1 SDALIE to all four subtypes of hFcgRs, with a modest increase in the binding affinity of cross-linked IgG1 SDALIE relative to wild-type IgG1. IgG2 displayed low binding affinity to activatory CD32a alone, but importantly there was no binding to the inhibitory CD32b, whereas the mutant IgG1 N297A demonstrated no binding to any low-affinity hFcgRs ( Figures 3A and 3B) .
We first assessed their capacity to deplete CTLA-4-expressing target cells in vitro in the presence of monocyte-derived human macrophages at varying effector to target (E:T) cell ratios ( Figure 3C ). As predicted, based on affinity for FcgRs expressed on monocyte-derived human macrophages ( Figure S3 ), which mirrored human melanoma, the IgG1 and IgG2 mAbs demonstrated superior ADCC activity relative to IgG1 N297A . Furthermore, the IgG1 SDALIE mAb, which has an optimized A:I FcgRbinding ratio, promoted enhanced ADCC activity relative to all evaluated isoforms at E:T ratios of 5:1 and above. IgG2-mediated depletion appeared CD32a dependent, as previously described (Schneider-Merck et al., 2010) , with loss of activity upon CD32a blockade or use of an Fc-silent deglycosylated form of IgG2 (IgG2 EndoS , Figure 3D ). 
Intra-tumoral
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IgG2 EndoS mAb or in hFcgR mice lacking expression of CD32a (FCGR2A À/À ) ( Figure S4 ).
As previously described in wild-type mice (Simpson et al., 2013) , the depleting activity of all human IgG variants in this model was restricted to the tumor microenvironment, with no impact on Treg cells in LNs or blood ( Figure 4A) . As a result, anti-CTLA-4 mAb of human IgG1, IgG1 SDALIE , and IgG2 isotypes led to an increase in the intra-tumoral ratio of CD8 + to Treg cells ( Figure 4B ). This was only observed within the tumor microenvironment, demonstrating that, in the context of human FcgRhuman IgG interactions in vivo, depletion of tumor-infiltrating Treg cells is a major contributor to the shift in this ratio, which has previously been associated with therapeutic responses in mouse and humans (Hodi et al., 2008; Quezada et al., 2006) . Treg cell depletion also correlated with a higher proliferation of CD4 + eff and CD8 + T cells independently of the isotype, although only the IgG1 SDALIE mAb resulted in a significantly higher production of interferon-g (IFNg) by CD4 + eff T cells ( Figures 4C and 4D ). In order to determine the impact of intra-tumoral Treg cell depletion on anti-tumor activity and survival, hFcgR mice were challenged with subcutaneous MCA205, MC38, or B16 tumors on day 0 and subsequently treated with chimeric anti-mCTLA-4 mAb IgG variants on days 6, 9, and 12. Among MCA205 tumors, growth was equivalent in mice left untreated or in those treated with the Fc-silent IgG1 N297A anti-mCTLA-4. This finding was of key relevance, demonstrating that CTLA-4 blockade alone is insufficient to promote tumor rejection in the context of human FcgR-IgG interactions. In contrast, the majority of mice treated with either IgG1 or IgG2 anti-CTLA-4 mAbs rejected tumors completely (66.67% and 80%, respectively). Anti-CTLA-4 IgG1 SDALIE , with enhanced affinity for activating FcgRs, resulted in eradication of established tumors in all treated mice ( Figure 4E ). Importantly, responses appeared durable, with responding mice from all treatment groups alive for more than 80 days ( Figure 4F ). Similar responses were observed among mice bearing MC38 tumors, where the therapeutic effect, although lower than in MCA205 tumors despite higher doses of mAbs, was only observed in the groups treated with depleting isotypes. Although the proportion of complete responses was higher in the IgG1 SDALIE group (75.0%) compared with the IgG1 and IgG2 treatments (66.67% and 62.5%, respectively), these differences were not statistically significant. In contrast, correlating with an observed paucity of both T and innate effector cell infiltration ( Figure S2A ), anti-CTLA-4 mAbs lacked efficacy against B16 tumors despite the use of a higher dose of antibody and regardless of isotype ( Figure 4F ).
Our pre-clinical data support a unifying hypothesis in which both hIgG1 and hIgG2 anti-CTLA-4 mAbs employed in the clinic act to promote preferential depletion of tumor-infiltrating Treg cells and increase the intra-tumoral Teff/Treg cell ratio associated with tumor rejection. The observed lack of activity against B16 melanoma indicates that such activity is likely only relevant to inflamed tumors with abundant target molecule expression and FcgR-expressing innate effector cell subsets. Further, our data suggest that optimization of A:I FcgR binding through Fc engineering may promote enhanced Treg cell depletion and anti-tumor activity in this context.
Human FcgR Polymorphisms Impact Response to Ipilimumab in Patients with Advanced Melanoma
In humans, the strongest evidence for a role of FcgR-mediated effector function in tumor-targeting antibody-based cancer therapies (e.g., rituximab) derives from studies demonstrating an association between clinical responses and specific alloforms of activating FcgRs conferring higher binding affinity to IgG1 or IgG2, particularly the CD16a-V158F and CD32a-H131R SNPs, respectively (Cartron et al., 2002; Musolino et al., 2008; Weng and Levy, 2003; Zhang et al., 2007) . However, no association between FcgR polymorphisms and clinical outcome has been described in the context of anti-CTLA-4 or other immune checkpoint modulators.
Mutational burden and putative neoantigen burden have been identified as predictive markers of response to ipilimumab in patients with advanced melanoma (Van Allen et al., 2015; McGranahan et al., 2016; Nathanson et al., 2016; Snyder et al., 2014) , pointing to mutations as a potential substrate for tumor recognition by T cells. More recently, tumor-specific indel mutations (insertion and deletions) have been identified as a highly immunogenic mutational class that can trigger an abundance of neoantigens and greater mutation binding specificity (Turajlic et al., 2017) . Since CTLA-4 is thought to be relevant in the context of T cell receptor engagement (Leach et al., 1996) , we sought to determine the impact of the CD16a-V158F and CD32a-H131R SNPs, identified through sequencing of germline DNA, on response to ipilimumab in two separate cohorts of patients with advanced melanoma (Van Allen et al., 2015; Snyder et al., 2014) (Figure 5 ). We hypothesized that response would be associated with higher non-synonymous single-nucleotide neoantigens (nsSNV neoAg) or indel mutational burden (i.e., a substrate T cell response that could be amplified by ipilimumab) and presence of the CD16a-V158F or CD32a-H131R SNP.
Among tumors with low indel burden (%median), the CD16-V158F polymorphism was not observed to have an impact on response. However, among those with high indel burden (>median), presence of the CD16-V158F SNP was associated with higher rates of response in both Van Allen et al. (2015) and Snyder et al. (2014) datasets ( Figure 5A, left graphs) . Metaanalysis of both datasets demonstrated significantly higher response rates in those with high indel burden and the CD16-V158F SNP, as compared with all other patients (p = 0.016). Similar findings were observed when considering nsSNV neoantigens and the presence or absence of the CD16-V158F ( Figure 5A , right graphs, p = 0.043). Once again, meta-analysis of both datasets demonstrated significantly higher response rates among those with high neoantigen burden (>median) and the CD16-V158F SNP. Further, in the Snyder et al. (2014) (2015) dataset, the differences were not statistically significant. Such observations were not common to the CD32a-H131R polymorphism, which is associated with greater affinity for IgG2 rather than IgG1 (Figures S5A and S5B) (Parren et al., 1992; Salmon et al., 1992) . Feasibly, improved response rates and survival in patients with the CD16-V158F SNP could also relate to enhancement of other immunological processes mediated by FcgR-expressing cell subsets, including antigen processing and presentation. However, analysis of a cohort of patients with advanced melanoma treated with pembrolizumab or nivolumab (Hugo et al., 2016) , both IgG4 mAbs directed against PD-1, with low predicted binding affinity to FcgRs, demonstrated no association between the CD16-V158F SNP and response rates in patients with high indel burden ( Figure S5C ). Indeed, response rates appeared lower in this setting (although not meeting significance). Intriguingly, the CD16-V158F allele is capable of binding to IgG4, raising the possibility that depletion of PD-1 high Teff cells via IgG4-mediated ADCC might underlie inferior response rates in those with high indel burden and CD16-V158F SNP. Finally, a clinically relevant potential surrogate of mutational burden is the magnitude of the immune infiltrate in the tumor. We therefore interrogated RNA sequencing (RNA-seq) data derived from the Van Allen et al. (2015) cohort and compared the expression of key immune markers in responding patients with high mutational load (based on either indel or putative neoantigen burden) and the CD16-V158F SNP with rest of the cohort. Expression levels of CD8A, cytolytic markers (granzyme A and perforin) as well as the CD8A/FoxP3 ratio (based on gene expression) appeared higher in the group with improved response ( Figure 5C ). Although the size of the cohort with RNA-seq data available in the Van Allen et al. (2015) dataset (n = 30) was too small to allow adequate statistical analysis, the presence of high indel or putative neoantigen burden, CD8A, and the CD16-V158F SNP was associated with higher response rates than any other combination of metrics ( Figure 5D ), supporting the hypothesis that, in inflamed or highly infiltrated tumors, anti-CTLA-4 antibodies function, at least in part, via engagement of FcgRs and depletion of Treg cells.
DISCUSSION
Pre-clinical studies in mouse models of cancer have demonstrated that the activity of certain immune modulatory antibodies may extend beyond receptor stimulation or blockade of Teff cells, relying upon concomitant depletion of Treg cells for maximal anti-tumor activity (Bulliard et al., 2013 (Bulliard et al., , 2014 Selby et al., 2013; Simpson et al., 2013) . Preferential depletion of tumor-infiltrating Treg cells by antibodies targeting CTLA-4, GITR, and OX40 depends upon both a higher density of the target molecule on intra-tumoral Treg cells compared with Teff cells and the presence of an appropriate population of cells to mediate ADCC. Despite the growing body of evidence supporting the premise that immune modulatory antibodies can bear dual (immune modulatory and Treg cell depleting) activity, less evidence exists to support that this mechanism of action is as important in the clinical context.
Here, we extend our previous findings by using hFcgR mice and chimeric anti-mCTLA-4 mAbs with human IgG variants to model the rules of engagement for human FcgRs and human IgGs in the context of immune modulatory mAbs, demonstrating that anti-human CTLA-4 mAbs work, at least in part, through depletion of tumor-infiltrating Treg cells. Anti-CTLA-4 mAbs with the same Fc variants employed in ipilimumab (IgG1) and tremelimumab (IgG2) both induced in vivo depletion of tumorinfiltrating Treg cells in the context of human FcgRs. Antibodies engineered to enhance this activity had improved anti-tumor activity, whereas those engineered to lack ADCC capacity demonstrated poor anti-tumor activity. The high expression of CTLA-4 in tumor-infiltrating Treg cells and the presence of innate effector cells expressing high levels of CD16 and CD32a activatory FcgRs both in mouse and humans likely explain the preferential local depletion in the tumor by both antibody isotypes.
A relevant finding was a lack of activity in B16 melanoma. This was associated with a paucity of T cell and innate effector cell infiltration and consequent lack of both target molecule expression and FcgR-expressing cell subsets. This was consistent with the observation that the CD16a-V158F polymorphism was associated with improved response rates in patients with advanced melanoma treated with ipilimumab, but only in the context of high putative neoantigen or indel burden. Taken together, these data provide potential explanation for the modest response rates observed to date with anti-CTLA-4 monotherapy (Schadendorf of mutational load were tested (McGranahan et al., 2016; Turajlic et al., 2017) : (left) the number of frameshift indel mutations and (right) the number of nonsynonymous single-nucleotide variant (nsSNV) neoantigens. In all cases, high and low are defined as above or below the median value, respectively. In each analysis, patient group (1) is tested for a difference in response rate compared with groups 2-4 using Fisher's exact test. Meta-analysis for each measure (p meta ), across the two patient cohorts was conducted using the Fisher's method of combining p values from independent tests. (B) Survival analysis of patients with advanced melanoma treated with anti-CTLA-4 with low (%median) or high (>median) predicted neoantigen burden with or without the germline polymorphism CD16a-V158F. Log rank p values are displayed with hazard ratio (HR) and confidence interval (CI). In (A) and (B), patients from the Snyder et al. (2014) See also Figure S5 . et al., 2015) and suggest that baseline non-inflamed tumors will require combination approaches which serve to promote immune infiltration. This might also explain the observed synergy with combination anti-CTLA-4 and anti-PD-1 therapy observed in clinical trials (Larkin et al., 2015; Wolchok et al., 2013) . Although the extent of the contribution of ADCC to the activity of ipilimumab and tremelimumab has not been formally tested, our mouse model suggests that it is potentially critical and that further enhancement of ADCC may result in enhanced antitumor activity and survival. Where ADCC activity is desirable, the IgG1 isotype is most commonly selected owing to its predicted binding affinity for activating FcgRs. However, the intratumoral composition of FcgR-expressing cell subsets is rarely considered, both in terms of the expression of individual FcgRs and their relative abundance. We have demonstrated in murine and human tumors that both the activatory FcgR CD16a and the inhibitory receptor CD32b appeared upregulated on tumorassociated macrophages relative to LN and blood. In keeping with this, IgG1 SDALIE mAb, with an optimized A:I (CD16:CD32b) binding profile, demonstrated superior anti-tumor activity relative to all evaluated chimeric anti-CTLA-4 Fc variants. Although not meeting significance, this is likely to be the result of the improved efficacy of intra-tumoral Treg cell depletion observed for IgG1 SDALIE relative to wild-type IgG1 and consequent higher production of IFNg by CD4 + eff T cells in the tumor. In contrast to the IgG1 isotype, IgG2 is generally regarded as a poor mediator ADCC owing to a relatively low affinity for activatory FcgRs, particularly CD16 (Bruhns et al., 2009 ), the principal receptor involved in NK cell-mediated ADCC. However, the Fc effector functions of IgG2 are mediated by CD32a and in vitro data demonstrate that IgG2 mAbs mediate effective ADCC via CD32a-expressing myeloid cells (Schneider-Merck et al., 2010) . In support of these findings, we demonstrated that chimeric anti-mCTLA-4 IgG2 mAb depletes intra-tumoral Treg cells in vivo to a similar extent as the IgG1 mAb. These results may be explained by the relative abundance of CD32a-expressing tumor-infiltrating myeloid cells, which are more abundant than CD16 + NK cells both in murine tumors and human melanoma. Furthermore, the binding of IgG2 to inhibitory CD32b is minimal, resulting in a high A:I (CD32a:CD32b) ratio that favors Fc effector function. These results raise the possibility that Treg cell depletion is also relevant to the activity of tremelimumab and that FcgR polymorphisms may contribute to its activity, since the CD32a-H131R polymorphism confers higher relative binding affinity to IgG2 (Bruhns et al., 2009; Sanders et al., 1995; Schneider-Merck et al., 2010) .
Further co-stimulatory and co-inhibitory receptors of clinical relevance, specifically GITR, ICOS, and OX40, exhibited similar expression profiles to that of CTLA-4 and may be better targeted with antibodies displaying dual activity. Target molecule density, antibody isotype, and the intra-tumoral composition of FcgRexpressing cell subsets must all be considered in the design of immune modulatory mAbs. Optimal intra-tumoral ADCC activity may depend on CD16a or CD32a binding, depending on which innate effector cells are enriched within the tumor microenvironment. However, ADCC activity only appears relevant in the context of an inflamed tumor microenvironment, and prospective clinical studies should consider exploring the use of polymorphism status and mutational burden to better identify those patients likely to respond to immune modulatory antibodies armed with dual activity, with appropriate stratification to combination regimens that promote tumor infiltration in those with cold tumors at baseline.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice C57BL/6 and BALB/c mice were purchased from Charles River Laboratories. FcgRa -/-human FcgR transgenic mice of C57BL/6 background were kindly provided by J. V. Ravetch (The Rockefeller University, New York, USA) and housed and bred in Charles River Laboratories, U.K. FCGR2A -/-mice were derived from the same colony. Experiments were performed with 6-10 week old females randomly assigned to experimental groups. All animal studies were performed under University College London and U.K. Home Office ethical approval and regulations.
Cell Lines and Tissue Culture MCA205 cells were cultured in Dulbecco's modified Eagle medium (DMEM, Sigma) supplemented with 10% fetal calf serum (FCS, Sigma), 100 U/mL penicillin, 100 mg/mL streptomycin and 2 mM L-glutamine (all from Gibco). MC38, CT26, B16 and SupT1 cells were cultured in Roswell Park Memorial Institute (RPMI) media supplemented as above. A cell line with stable expression of murine CTLA-4 was generated by retroviral transduction of Sup-T1 cells. For generation of human macrophages, monocytes were isolated from healthy donor PBMCs using anti-CD14 microbeads (Miltenyi Biotec) and cultured for 7 days in supplemented RPMI with recombinant human macrophage colony-stimulating factor (M-CSF, 50 ng/mL, Cell Guidance Systems).
Human Study Oversight
Presented human data derives from three translational studies, each approved by local institutional review board and Research Ethics Committee (Melanoma -REC no. 11/LO/0003, The Royal Marsden NHS Foundation Trust; NSCLC -REC no.13/LO/1546, University College London Hospital and RCC -REC no. 11/LO/1996, The Royal Marsden NHS Foundation Trust). All were conducted in accordance with the provisions of the Declaration of Helsinki and with Good Clinical Practice guidelines as defined by the International Conference on Harmonization. All patients (or their legal representatives) provided written informed consent before enrolment. Patient demographics are displayed in Tables S1 and S2 .
METHOD DETAILS
Antibody Production
Antibodies were produced in Evitria AG (Switzerland). The sequences of the variable regions of the heavy and light chains of antimouse CTLA-4, clone 4F10, were kindly provided by J. A. Bluestone (University of California, San Francisco, U.S.A.) and used to generate chimeric antibodies with the constant regions of human IgG1 and IgG2 heavy chains and k light chain, as well as the mutated IgG1 variants N297A and S239D/A330L/I332E (SDALIE) (Lazar et al., 2006) . IgG2 antibodies were deglycosylated with Endo S endoglycosydase and re-purified with chitin microbeads following the manufacturer's protocol (New England Biolabs).
Surface Plasmon Resonance (SPR)
The binding of different human antibody isotypes or Fc-engineered variants of chimeric anti-CTLA-4 to human FcgRs was evaluated by surface plasmon resonance (SPR) using a Biacore 3000 instrument (GE Healthcare). Goat Anti-human-F(ab)' 2 antibody (100 mg/ ml, Jackson Immunoresearch) was immobilized to a CM5 chip using standard amine coupling with a flow rate of 10 ml/min for 10 min. Anti-CTLA-4 mAbs were diluted to 50 mg/ml and added to the surface for 3 min at 10 ml/min. His tagged human FcgRI, FcgRIIa, FcgRIIb and FcgRIII (R&D Systems) were added at 1500, 500, 167, 56 and 16nM to the surface for 1 min at 30 ml/min followed by 5 min dissociation. After each cycle the surface was regenerated twice with glycine buffer pH 1.5. For experiments with crosslinked Fc receptor, Fc-receptors were pre incubated with anti-histidine antibody (R&D Systems) at a 2:1 molar ratio before addition to the surface at 1500, 500, 167, 56 and 16nM.
In Vitro ADCC Assay SupT1 cells expressing murine CTLA-4 were labelled with 5 mM carboxyfluorescein succinimidyl ester (CellTrace CFSE Cell Proliferation Kit, Life Technologies) and co-cultured overnight with human macrophages at the indicated ratios in the presence of the indicated mAbs (10 mg/mL). For blocking of FcgRs, macrophages were incubated with anti-CD32a (clone 2E08, Bioinvent) or anti-CD32b (clone 6G11, Bioinvent) F(ab') 2 fragments at 50 mg/mL for 30 min at 37 C before adding the therapeutic antibodies and target cells. The absolute number of CFSE-labelled cells in each condition was then quantified by flow cytometry using a defined number of reference fluorescent beads (Cell Sorting Set-up Beads for UV Lasers, ThermoFisher). The percentage of killing was determined as: 100-(number CFSE + targets treated/number CFSE + targets untreated).
